Keywords
arthralgia
pathogenesis
diagnosis
prevention
Abstract
Chikungunya virus is an Alphavirusthat possesses characteristics similar to that of an arthropod-borne virus. Chikungunya virus has been one of the major concerns for the last few decades due to its nature of explosive spreading throughout the world. This article is intended to give detailed information about Chikungunya virus, and includes its pathogenesis, origins, diagnosis, treatment and prevention. Although, recent researches suggests various approaches to treating Chikungunya virus, extensive literature search on Chikungunya virus has revealed that, currently, there is no effective treatment available and the virus is greatly dependent on its vectors. Patients affected by Chikungunya virus mainly show symptoms of fever, arthralgia, joint pain and skin rash. Since there is no effective treatment available, public awareness is the most significant factor for potential prevention against Chikungunya virus.
References
1. Schuffenecker I, Iteman I, Michault A, Murri S, Frangeul L, Vaney MC, et al. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med. 2006;3(7):263.
2. Deller JJ, Russell PK. An analysis of fevers of unknown origin in American soldiers in Vietnam. Ann Inter Med. 1967;66(6):1129-43.
3. McGill PE. Viral infections: α-viral arthropathy. Best Prac & Res Clin Rheumat. 1995;9(1):145-50.
4. Adebajo AO. Rheumatic manifestations of tropical diseases. Curr Opin Rheumatol. 1996;8(1):85-9.
5. Ligon BL. Reemergence of an unusual disease: the chikungunya epidemic. In Seminars in pediatric infectious diseases. WB Saunders. 2006:17(2):99-104.
6. Yadav P, Gokhale MD, Barde PV, Singh DK, Mishra AC, Mourya DT. Experimental transmission of Chikungunya virus by Anopheles stephensi mosquitoes. Act Virol. 2003;47(1):45-7.
7. Pialoux G, Gaüzère BA, Jauréguiberry S, Strobel M. Chikungunya, an epidemic arbovirosis. Lan Infect Dis. 2007;7(5):319-27.
8. Diallo M, Thonnon J, Traore-Lamizana M, Fontenille D. Vectors of Chikungunya virus in Senegal: current data and transmission cycles. Am J Trop Med and Hyg. 1999;60(2):281-6.
9. Jupp PG. Chikungunya virus disease. Arbovirus: epidemiology and ecology. 1988:137.
10. Ng LC, Hapuarachchi HC. Tracing the path of Chikungunya virus – evolution and adaptation. Infect Gen Evol. 2010;10(7):876-85.
11. Robinson MC. An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features. Trans R Soc Trop Med Hyg. 1955;49(1):28-32.
12. Bandeira AC, Campos GS, Sardi SI, Rocha VF, Rocha GC. Neonatal encephalitis due to Chikungunya vertical transmission: first report in Brazil. ID Cases. 2016;5:57-9.
13. Khan AH, Morita K, del Carmen Parquet M, Hasebe F, Mathenge EG, Igarashi A. Complete nucleotide sequence of chikungunya virus and evidence for an internal polyadenylation site. J Gen Virol. 2002;83(12):3075-84.
14. Strauss JH, Strauss EG. The alphaviruses: gene expression, replication, and evolution. Microbiol reviews. 1994;58(3):491-562.
15. Yadav P, Shouche YS, Munot HP, Mishra AC, Mourya DT. Genotyping of Chikungunya virus isolates from India during 1963-2000 by reverse transcription-polymerase chain reaction. Act Virol. 2003;47(2):125.
16. Vanlandingham DL, Hong C, Klingler K, Tsetsarkin K, McElroy KL, Powers AM, et al. Differential infectivities of o’nyong-nyong and chikungunya virus isolates in Anopheles gambiae and Aedes aegypti mosquitoes. Am J Trop Med Hyg. 2005;72(5):616-21.
17. Jupp PG, McIntosh BM, Dos Santos I, De Moor P. Laboratory vector studies on six mosquito and one tick species with chikungunya virus. Trans R Soc Trop Med Hyg. 1981;75(1):15-9.
18. Rao TR. Vectors of dengue and chikungunya viruses: a brief review. Ind J Med Res. 1964;52:719-26.
19. R. C. Kading, E. M. Borland, M. Cranfield, A. M. Powers. Prevalence of antibod-ies to alphaviruses and flaviviruses in free-ranging game animals and nonhuman primates in the greater congo basin. J Wildl Dis. 2013;49:587-599.
20. Lam SK, Chua KB, Hooi PS, Rahimah MA, Kumari S, Tharmaratnam M, et al. Chikungunya infection-an emerging disease in Malaysia. Southeast A J Trop Med Pub Health. 2001 Sep;32(3):447-51.
21. Van den Bosch C. A role for RNA viruses in the pathogenesis of Burkitt’s lymphoma: the need for reappraisal. Adv Hematol. 2012; 2012.
22. Borgherini G, Poubeau P, Staikowsky F, Lory M, Moullec NL, Becquart JP, et al. Outbreak of chikungunya on Reunion Island: early clinical and laboratory features in 157 adult patients. Clin Infect Dis. 2007 Jun 1;44(11): 1401-7.
23. Queyriaux B, Simon F, Grandadam M, Michel R, Tolou H, Boutin JP. Clinical burden of chikungunya virus infection. Lan Infect Dis. 2008;8(1):2-3.
24. Lemant J, Boisson V, Winer A, Thibault L, André H, Tixier F, et al. Serious acute chikungunya virus infection requiring intensive care during the Reunion Island outbreak in 2005-2006. Crit care Med. 2008;36(9):2536-41.
25. Simon F, Parola P, Grandadam M, Fourcade S, Oliver M, Brouqui P, et al. Chikungunya infection: an emerging rheumatism among travelers returned from Indian Ocean islands. Report of 47 cases. Med. 2007;86(3):123-37.
26. Sissoko D, Malvy D, Ezzedine K, Renault P, Moscetti F, Ledrans M, et al. Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period. PLoS Negl Trop Dis. 2009;3(3):e389.
27. Manimunda SP, Vijayachari P, Uppoor R, Sugunan AP, Singh SS, Rai SK, et al. Clinical progression of chikungunya fever during acute and chronic arthritic stages and the changes in joint morphology as revealed by imaging. Trans R Soc Trop Med Hyg. 2010;104(6):392-9.
28. Brighton SW, Prozesky OW, De La Harpe AL. Chikungunya virus infection-A retrospective study of 107 cases. South Afr Med J. 1983;68(9):313-5.
29. Borgherini G, Poubeau P, Jossaume A, Gouix A, Cotte L, Michault A, et al. Persistent arthralgia associated with chikungunya virus: a study of 88 adult patients on reunion island. Clin Infect Dis. 2008; 47(4):469-75.
30. Thiberville SD, Boisson V, Gaudart J, Simon F, Flahault A, De Lamballerie X. Chikungunya fever: a clinical and virological investigation of outpatients on Reunion Island, South-West Indian Ocean. PLoS Negl Trop Dis. 2013;7(1):e2004.
31. Sissoko D, Ezzedine K, Moendandzé A, Giry C, Renault P, Malvy D. Field evaluation of clinical features during chikungunya outbreak in Mayotte, 2005–2006. Trop Med & Int Health. 2010;15(5):600-7.
32. Zim MM, Sam IC, Omar SS, Chan YF, AbuBakar S, Kamarulzaman A. Chikungunya infection in Malaysia: comparison with dengue infection in adults and predictors of persistent arthralgia. J Clin Virol. 2013;56(2):141-5.
33. Staikowsky F, Talarmin F, Grivard P, Souab A, Schuffenecker I, Le Roux K, et al. Prospective study of Chikungunya virus acute infection in the Island of La Reunion during the 2005-2006 outbreak. PloS one. 2009;4(10):e7603.
34. Nkoghe D, Kassa RF, Caron M, Grard G, Mombo I, Bikié B, et al. Clinical forms of chikungunya in Gabon, 2010. PLoS Negl Trop Dis. 2012;6(2):e1517.
35. Kimani J, Osanjo GO, Sang R, Ochieng J, Mulaa F. Development of Dromedary Antibody-based Enzyme Linked Immunosorbent Assay for Detecting Chikungunya virus Infections. Afr J Pharm Therap. 2017;6(2);109-16.
36. Galo SS, González K, Téllez Y, García N, Pérez L, Gresh L, et al. Development of in-house serological methods for diagnosis and surveillance of chikungunya. Rev Panam de Sal Públ. 2017;41:e56.
37. Agarwal A, Singh AK, Sharma S, Soni M, Thakur AK, Gopalan N, et al. Application of Real-time RT-PCR in vector surveillance and assessment of replication kinetics of an emerging novel ECSA genotype of Chikungunya virus in Aedes aegypti. J Virol Meth. 2013;193(2):419-25.
38. Chen H, Takei F, Koay ES, Nakatani K, Chu JJ. A novel DANP-coupled hairpin RT-PCR for rapid detection of Chikungunya virus. J Mol Diagn. 2013;15(2):227-33.
39. Rueda JC, Angarita JI, Santos AM, Saldarriaga EL, Pelaez-Ballestas I, Lόpez-Morales P, et al. SAT0574 Performance of immunoglobulin M and G (IGM and IGG) antibodies against chikungunya virus (CHIKV) by enzyme-linked immunosorbent (ELISA) technique. Ann Rheum Dis. 2017;76:993.
40. Smee DF, Alaghamandan HA, Kini GD, Robins RK. Antiviral activity and mode of action of ribavirin 5'-sulfamate against Semliki Forest virus. Antv Res. 1988;10(6):253-62.
41. Abdelnabi R, Neyts J, Delang L. Chikungunya virus infections: time to act, time to treat. Curr Opin Virol. 2017;24:25-30.
42. Ravichandran R, Manian M. Ribavirin therapy for Chikungunya arthritis. J Infect Developing Countries. 2008;2(02):140-2.
43. Briolant S, Garin D, Scaramozzino N, Jouan A, Crance JM. In vitro inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-α and ribavirin combination. Antv Res. 2004;61(2):111-7.
44. Guzzetta G, Trentini F, Poletti P, Baldacchino FA, Montarsi F, Capelli G, et als. Effectiveness and economic assessment of routine larviciding for prevention of chikungunya and dengue in temperate urban settings in Europe. PLoS Negl Trop Dis. 2017;11(9):e0005918.
45. Powers AM. Vaccine and Therapeutic Options To Control Chikungunya Virus. Clin Mbio Reviews. 2018;31(1):e00104-16.
46. Muthumani K, Block P, Flingai S, Muruganantham N, Chaaithanya IK, Tingey C, et al. Rapid and long-term immunity elicited by DNA-encoded antibody prophylaxis and DNA vaccination against chikungunya virus. J Infect Dis. 2016;214(3):369-78.
47. Rowland RR, Yoo D. Nucleolar-cytoplasmic shuttling of PRRSV nucleocapsid protein: a simple case of molecular mimicry or the complex regulation by nuclear import, nucleolar localization and nuclear export signal sequences. Vir Res. 2003;95(1-2):23-33.
48. Taylor A, Liu X, Zaid A, Goh LY, Hobson-Peters J, Hall RA, et al. Mutation of the n-terminal region of chikungunya virus capsid protein: Implications for vaccine design. Mbio. 2017;8(1): e01970-16.
49. Roques P, Ljungberg K, Kümmerer BM, Gosse L, Dereuddre-Bosquet N, Tchitchek N, et al. Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus. JCI Ins. 2017;2(6);1-20.
50. Tangy F, Brandler S, Despres P, Habel A, inventors; THEMIS BIOSCIENCE GMBH, Institut Pasteur, Centre National de la Recherche Scientifique CNRS, assignee. Recombinant measles virus expressing Chikungunya virus polypeptides and their applications. United States patent US 9,655,961. 2017.
51. Fradin MS, Day JF. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med. 2002;347(1):13-8.
52. Mirzaian E, Durham MJ, Hess K, Goad JA. Mosquito‐Borne illnesses in travelers: a review of risk and prevention. Pharmtherap: J Human Pharm Drug Therap. 2010;30(10):1031-43.
53. Nasci RS, Zielinski-Gutierrez E, Wirtz RA, Brogdon WG. Protection against mosquitoes, ticks, other insects and arthropods. 2014 (Yellow book).
54. Patterson J, Sammon M, Garg M. Dengue, Zika and Chikungunya: emerging arboviruses in the new world. Westn J Emerg Med. 2016; 17(6):671.
55. Chang LJ, Dowd KA, Mendoza FH, Saunders JG, Sitar S, Plummer SH, et al. Safety and tolerability of Chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lan. 2014; 384(9959):2046-52.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2019 Autors